These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 21083471

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Plasma cell leukemia].
    Ravinet A, Bay JO, Tournilhac O.
    Bull Cancer; 2014 Nov; 101(11):1048-58. PubMed ID: 25418598
    [Abstract] [Full Text] [Related]

  • 8. Multiple myeloma.
    Kyle RA, Rajkumar SV.
    N Engl J Med; 2004 Oct 28; 351(18):1860-73. PubMed ID: 15509819
    [No Abstract] [Full Text] [Related]

  • 9. Clinical impact of chromosomal aberrations in multiple myeloma.
    Nahi H, Sutlu T, Jansson M, Alici E, Gahrton G.
    J Intern Med; 2011 Feb 28; 269(2):137-47. PubMed ID: 21158983
    [Abstract] [Full Text] [Related]

  • 10. New developments in the treatment of patients with multiple myeloma.
    Minnema MC, van der Spek E, van de Donk NW, Lokhorst HM.
    Neth J Med; 2010 Jan 28; 68(1):24-32. PubMed ID: 20103818
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Retrospective case series of three patients with plasma cell leukemia treated with bortezomib-based regimens.
    Mele G, Pinna S, Melpignano A, Quarta G.
    Clin Ther; 2010 May 28; 32(5):915-9. PubMed ID: 20685499
    [Abstract] [Full Text] [Related]

  • 13. Multiple myeloma - current issues and controversies.
    Kumar S.
    Cancer Treat Rev; 2010 May 28; 36 Suppl 2():S3-11. PubMed ID: 20472186
    [Abstract] [Full Text] [Related]

  • 14. Emergence of central nervous system myeloma in the era of novel agents.
    Gangatharan SA, Carney DA, Prince HM, Wolf MM, Januszewicz EH, Ritchie DS, Harrison SJ.
    Hematol Oncol; 2012 Dec 28; 30(4):170-4. PubMed ID: 22144117
    [Abstract] [Full Text] [Related]

  • 15. Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
    Musto P, Falcone A, Sanpaolo G, Guglielmelli T, Zambello R, Balleari E, Catalano L, Spriano M, Cavallo F, La Sala A, Mantuano S, Nobile M, Melillo L, Scalzulli PR, Dell'Olio M, Bodenizza C, Greco MM, Carella AM, Merla E, Carella AM, Boccadoro M, Cascavilla N, Palumbo A.
    Leuk Res; 2006 Mar 28; 30(3):283-5. PubMed ID: 16111749
    [Abstract] [Full Text] [Related]

  • 16. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M.
    J Clin Oncol; 2010 Feb 10; 28(5):800-7. PubMed ID: 20048187
    [Abstract] [Full Text] [Related]

  • 17. [New treatment strategy of multiple myeloma for cure].
    Murakami H, Handa H.
    Gan To Kagaku Ryoho; 2006 Apr 10; 33(4):417-23. PubMed ID: 16612147
    [Abstract] [Full Text] [Related]

  • 18. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA, Sharma M, Higa GM.
    Ann Pharmacother; 2009 Feb 10; 43(2):329-38. PubMed ID: 19193585
    [Abstract] [Full Text] [Related]

  • 19. Novel agents for relapsed and/or refractory multiple myeloma.
    Thomas SK, Richards TA, Weber DM.
    Cancer J; 2009 Feb 10; 15(6):485-93. PubMed ID: 20010168
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.